Abstract
In this article, the authors focus in particular on section 56 of the Social Security Law (LFSS) for 2018, which provides for the possibility for the Health product economic Comity (CEPS) to set a unified tariff for drugs on the list in addition to generic and biosimilar drugs. By imposing the same reimbursement basis for generics as for originators or biosimilar and their reference medicinal product, the LFSS aims to remove the incentive for health establishments to choose to list a more expensive medicinal product in the hope of benefiting from a possible profit-sharing margin. The liability tariff then becomes a selling price limit. In addition, section 56 of the LFSS for 2018 repeals the system of flat-rate reduction of the hospitalization tariff when a drug on the list in addition is used for the purpose, in particular, of simplifying the conditions under which these products are covered. The authors indicate that the extension of the single tariff to all comparable specialties in terms of indications or therapeutic aim is likely to have a significant impact provided that it is known on which criterion comparability should be established.